While some studies have suggested an association between TET2 mutations and adverse outcomes, the evidence remains inconclusive (11–14) Furthermore, the clonal status of TET2 mutations—whether dominant or subclonal—and their mutation burden, as reflected by variant allele frequency (VAF), have not been systematically studied in CN-AML. Here, TET2 is linked to acute myeloid leukemia.